ReviewAlzheimer's research & therapy2017
Communicating mild cognitive impairment diagnoses with and without amyloid imaging.
Review in Alzheimer's research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.Alzheimer's research & therapy · 2018Pooled it
- Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Trial
- EEG microstates, spectral analysis, and risk prediction in epilepsy comorbid with mild cognitive impairment: alteration in intrinsic brain activity.Journal of translational medicine · 2025Article
- [Alzheimer's and Its Diagnosis: Are We Prepared to Accompany Our Patients? Shared Care Planning as a Relational Framework].Revista de neurologia · 2025Article
- "There has to be more caring": patient and care partner experiences of the disclosure of amyloid-β PET scan results.Aging & mental health · 2025Article
- Applying recommendations for diagnostic disclosure of mild cognitive impairment and dementia: Practical guidance for clinicians.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Observational
- Communicating the risk of dementia: a scoping review.BMJ neurology open · 2025Article
- Delivery of Neuropsychological Interventions for Adult and Older Adult Clinical Populations: An Australian Expert Working Group Clinical Guidance Paper.Neuropsychology review · 2024Review
- Counseling and disclosure practices in predictive Alzheimer's disease diagnostics: A scoping review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Psychological outcomes of dementia risk estimation in MCI patients: Results from the PreDADQoL project.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The expectations and experiences of patients regarding the diagnostic workup at a specialized memory clinic: An interview study.Health expectations : an international journal of public participation in health care and health policy · 2024Article
- Apolipoprotein E Genetic Testing in a New Age of Alzheimer Disease Clinical Practice.Neurology. Clinical practice · 2024Article
- Alzheimer's Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners.The journal of prevention of Alzheimer's disease · 2024Article
- Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2024Article
- A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants.The journal of prevention of Alzheimer's disease · 2024Article
- [Mild cognitive impairment in geriatric practice: patient orientation, diagnostics, treatment and ethics].Zeitschrift fur Gerontologie und Geriatrie · 2023Review
- Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum.Neurology · 2023Article
- Towards a future where Alzheimer's disease pathology is stopped before the onset of dementia.Nature aging · 2023Review
- "Now at least we have something to call it": Patient and care partner experiences receiving an amyloid PET scan.Journal of the American Geriatrics Society · 2022Article
- Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?Journal of Alzheimer's disease : JAD · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundMild cognitive impairment (MCI) has an uncertain etiology and prognosis and may be challenging for clinicians to discuss with patients and families. Amyloid imaging may aid specialists in determining MCI etiology and prognosis, but creates novel challenges related to disease labeling.
methodsWe convened a workgroup to formulate recommendations for clinicians providing care to MCI patients.
resultsClinicians should use the MCI diagnosis to validate patient and family concerns and educate them that the patient's cognitive impairment is not normal for his or her age and education level. The MCI diagnosis should not be used to avoid delivering a diagnosis of dementia. For patients who meet Appropriate Use Criteria after standard-of-care clinical workup, amyloid imaging may position specialists to offer more information about etiology and prognosis. Clinicians must set appropriate expectations, including ensuring that patients and families understand the limitations of amyloid imaging. Communication of negative results should include that patients remain at elevated risk for dementia and that negative scans do not indicate a specific diagnosis or signify brain health. Positive amyloid imaging results should elicit further monitoring and conversations about appropriate advance planning. Clinicians should offer written summaries, including referral to appropriate social services.
conclusionsIn patients with MCI, there is a need to devote considerable time and attention to patient education and shared decision-making. Amyloid imaging may be a tool to aid clinicians. Careful management of patient expectations and communication of scan results will be critical to the appropriate use of amyloid imaging information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.